Immune Memory After Papillomavirus Vaccination (IMAP-I) Study.

Trial Profile

Immune Memory After Papillomavirus Vaccination (IMAP-I) Study.

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Sep 2016

At a glance

  • Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
  • Indications Cervical cancer; Human papillomavirus infections
  • Focus Biomarker; Pharmacodynamics
  • Acronyms IMAP-1
  • Most Recent Events

    • 09 Apr 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 09 Apr 2012 Planned end date changed from 1 Jan 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov.
    • 10 Jan 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top